Article citationsMore >>

D. K. Packham et al., “Relative incidence of ESRD versus cardiovascular mortality in proteinuric type 2 diabetes and nephropathy: Results from the DIAMETRIC (Diabetes Mellitus Treatment for Renal Insufficiency Consortium) database,” American Journal of Kidney Diseases, vol. 59, no. 1. pp. 75-83, 2012.

has been cited by the following article:

Article

Effect of Genistein on Interleukin 1β and Transforming Growth Factor β in Diabetic Rat

1Biomedic, Sekolah Tinggi Ilmu Kesehatan Syedza Saintika, Padang, Indonesia

2Nutrition, Universitas Andalas, Padang, Indonesia

3Nursing, Sekolah Tinggi Ilmu Kesehatan Syedza Saintika, Padang, Indonesia


Journal of Food and Nutrition Research. 2019, Vol. 7 No. 4, 287-290
DOI: 10.12691/jfnr-7-4-5
Copyright © 2019 Science and Education Publishing

Cite this paper:
Putri Dafriani, Nur Indrawati Lipoeto, Honesty Diana Morika, Eliza Arman, Weni Sartiwi, Annita. Effect of Genistein on Interleukin 1β and Transforming Growth Factor β in Diabetic Rat. Journal of Food and Nutrition Research. 2019; 7(4):287-290. doi: 10.12691/jfnr-7-4-5.

Correspondence to: Putri  Dafriani, Biomedic, Sekolah Tinggi Ilmu Kesehatan Syedza Saintika, Padang, Indonesia. Email: putridafrianiabd@gmail.com

Abstract

One of diabetic complications is diabetes nephropathy. Nephropathy is caused by oxidative stress. Oxidative stress causes an inflammatory response that continues to the kidney fibrosis. Genistein can reduce proinflammatory citokines. This study aims to examine the effect of genistein on levels of IL-1β, TGF-β, HSP 47 and type IV collagen. This study was experimental. This study use 25 male wistar rats as experimental animals. Rats were divided into five groups, normal rats , hyperglycemic rats, hyperglycemic rats with administration of genistein 0.5 mg/kgw, hyperglycemic rats with administration of genistein 1 mg/kgw, hyperglycemic rats with genistein 2 mg/kgw. Streptozotocin given 65 mg/kgw by intraperitonal injection. The duration of administration of genistein is 4 weeks. The average levels of IL-1β in non-diabetic control group was 181.436 pg/ml, diabetic control 359.303 pg/ml, STZ: G 0.5 mg/kgw 265.088 pg/ml, STZ; G 1 mg/kgw 240.088 pg/ml and STZ; G 2 mg/kgw 120.344 pg/ml with p value of 0.000 (p < 0.05), it means that there is the effect of genistein on the levels of IL-1β in diabetic. The average levels of TGF-β in non diabetic control group was 1411.462 pg/ml, diabetic control 8492.520 pg/ml, STZ; G 0.5 mg/kgw 7334.098 pg/ml, STZ; G 1 mg/kgw 6134.568 pg/ml and STZ; G 2 mg/kgw 5012.616 pg/ml with p value of 0.000 (p < 0.05), which means that there is the effect of genistein on the levels of TGF-β. Genistein can reduce fibrosis by reducing levels of IL-1β and TGF-β.

Keywords